NeuroDerm
Ltd. (NDRM) is a pharmaceutical company focused on developing and
commercializing drug-device combinations for the treatment of central
nervous system (CNS) disorders, such as Parkinson's disease,
Alzheimer's disease, and schizophrenia. The company's product
candidates are designed to address significant unmet medical needs by
delivering drugs through continuous subcutaneous administration, which
may provide more consistent drug levels and improved efficacy compared
to current oral or injection therapies.
NeuroDerm's lead
product candidate is ND0612, a levodopa/carbidopa liquid formulation
that is delivered continuously through a subcutaneous patch pump.
ND0612 is being developed for the treatment of Parkinson's disease and
is currently in Phase III clinical trials. The company's other product
candidates include ND0701, a combination therapy for the treatment of
Alzheimer's disease, and ND0801, a combination therapy for the
treatment of schizophrenia.
NeuroDerm was founded in 2003 and
is headquartered in Rehovot, Israel. The company went public on the
NASDAQ Global Mark
NeuroDerm
Ltd. (NDRM) is a pharmaceutical company focused on developing and
commercializing drug-device combinations for the treatment of central
nervous system (CNS) disorders, such as Parkinson's disease,
Alzheimer's disease, and schizophrenia. The company's product
candidates are designed to address significant unmet medical needs by
delivering drugs through continuous subcutaneous administration, which
may provide more consistent drug levels and improved efficacy compared
to current oral or injection therapies.